email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
886 - 900
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
InnoRNA Raises $120 Million in B Round for mRNA Candidates
$5.00
Available
Brii Bio Partners with Sinopharm to Distribute COVID mAb Therapy in China
$5.00
Available
Biosion Out-Licenses Siglec-15 mAb for Solid Tumors in $226 Million Pact
$5.00
Available
CANbridge NDA for Rare Disease Therapy Accepted in Taiwan
$5.00
Available
Innovent Signs $45 Million Deal to Commercialize Two Lilly Oncology Drugs in China
$5.00
Available
InnoCare Approved to Start Trials of JH2 Inhibitor for Autoimmune Diseases
$5.00
Available
OBiO Completes Shanghai IPO for Gene-Cell CDMO Services; Trades 67% Higher
$5.00
Available
Ascentage Granted US Rare Pediatric Disease Status for Neuroblastoma Therapy
$5.00
Available
Recbio Plans to Raise $98 Million in a Hong Kong IPO for Vaccines
$5.00
Available
Nuance In-licenses Adult RSV Vaccine in $225 Million Deal
$5.00
Available
Simcere to Commercialize Lynk's JAK1 Inhibitor in China
$5.00
Available
China and US May Solve De-Listing Problem
$5.00
Available
Bioheng Approved to Start First China Trial of Universal CAR-T Therapy
$5.00
Available
EdiGene Licenses IP to Treat Genetically Caused Hemoglobin Diseases
$5.00
Available
Junshi Starts Global Phase III Trial of COVID-19 Therapy
$5.00
Available